{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-124911","form_type":"8-K","ticker":"IPSC","cik":"0001850119","company_name":"Century Therapeutics, Inc.","filed_at":"2023-12-11T23:59:59+00:00","discovered_at":"2026-05-14T18:03:31.043102+00:00","generated_at":"2026-06-07T15:05:21.322376+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Century Therapeutics presents initial CNTY-101 data supporting multi-dosing strategy at ASH","bullets":["Single-patient case study at Dose Level 1 (100 million cells) showed six-month durable complete response in high-risk R/R B-cell lymphoma","CNTY-101 was generally well tolerated with no dose-limiting toxicities, cytokine release syndrome, or neurotoxicity observed","Pharmacokinetic data suggested CNTY-101 exposure maintained upon additional cycles without lymphodepletion due to lack of allo-rejection","Company to host conference call Dec 11 to review additional clinical results from Dose Levels 1 and 2 and plans for systemic lupus erythematosus"],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-124911","json":"https://secwatch.observer/filing/0001104659-23-124911.json","markdown":"https://secwatch.observer/filing/0001104659-23-124911.md","text":"https://secwatch.observer/filing/0001104659-23-124911.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1850119/000110465923124911/0001104659-23-124911-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1850119/000110465923124911/tm2332547d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T15:05:21.322376+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}